Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Prednisone × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19 Lymphoma, Large B-Cell, Diffuse 11 Burkitt Lymphoma 11 Lymphoma, Follicular 9 Lymphoma 6 Prostatic Neoplasms, Castration-Resistant 5 Neoplasms 5 Lymphoma, Non-Hodgkin 5 Leukemia, Lymphocytic, Chronic, B-Cell 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, B-Cell, Marginal Zone 3 Hodgkin Disease 3 Waldenstrom Macroglobulinemia 2 Recurrence 2 Myasthenia Gravis 2 Carcinoma, Non-Small-Cell Lung 2 Vasculitis, Central Nervous System 1 Urogenital Neoplasms 1 Triple Negative Breast Neoplasms 1 Stiff-Person Syndrome 1 Skin Neoplasms 1 Rasmussen subacute encephalitis 1 Prostate Cancer, Hereditary, 7 1 Prostate Cancer Metastatic 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1 Plasmablastic Lymphoma 1 Ovarian Neoplasms 1 Opsoclonus-Myoclonus Syndrome 1

Interventions

fludrocortisone acetate 1 enzalutamide 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiosurgery 1 Prednisone 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1 Androgen Antagonists 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡